default author photo

Juan W. Valle

The Christie NHS Foundation Trust - Department of Medical Oncology

Wilmslow Road

Manchester, M20 4BX

United Kingdom

SCHOLARLY PAPERS

3

DOWNLOADS

265

TOTAL CITATIONS

1

Scholarly Papers (3)

1.

Randomised Phase 3 Study of Ivosidenib in IDH1-Mutant Chemotherapy-Refractory Cholangiocarcinoma

Number of pages: 261 Posted: 08 Dec 2019
Memorial Sloan Kettering Cancer Center - Department of Medicine, Hospital Vall d’Hebron, University of Texas at Houston - MD Anderson Cancer Center, University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, University of Wisconsin-Madison - Carbone Cancer Center, Hospital Universitario 12 de Octubre - Department of Medical Oncology, Harvard University - Dana-Farber Cancer Institute, University of Chicago - Pritzker School of Medicine, Mayo Clinic Hospital - Phoenix, University College London - UCL Cancer Institute, University of Washington - Department of Medicine, Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center, Seoul National University - Department of Internal Medicine, Utah Cancer Specialists, Trinity College (Dublin), Harvard University - Department of Medicine, University of Arizona - Department of Medicine, University of Southern California - Norris Comprehensive Cancer Center, Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., The Christie NHS Foundation Trust - Department of Medical Oncology and Harvard University - Cancer Center
Downloads 144 (511,933)

Abstract:

Loading...

Cholangiocarcinoma; IDH1 mutation; Ivosidenib; Phase 3 study

2.

Presentation, Management and Outcome of Cholangiocarcinoma in Europe: Results From Real-World Patient Registry

Number of pages: 75 Posted: 25 May 2021
Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, The Christie NHS Foundation Trust - Department of Medical Oncology, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Erasmus MC University Medical Center - Department of Surgery, University of Regensburg - Institute of Pathology, University of Amsterdam - Cancer Center Amsterdam, Department of Medical Oncology, Hospital Universitario 12 de Octubre - Department of Medical Oncology, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Humanitas University - Division of Internal Medicine and Hepatology, University of Padua - DMM Department of Molecular Medicine, Universidad de Navarra - Clinica Universidad de Navarra and Program in Solid Tumors (CIMA), Sorbonne Université - Department of Hepatobiliary and Liver Transplantation Surgery, Sapienza University of Rome - Translational and Precision Medicine, University of Glasgow - Institute of Cancer Sciences, University of Sassari - Department of Medical, Surgical and Experimental Sciences, University of Glasgow - Institute of Cancer Sciences, Carlos III National Institute of Health - Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Klinik Favoriten - Department for Surgery, Università Politecnica delle Marche - Department of Gastroenterology, Medical University of Warsaw - Department of General, Transplant and Liver Surgery, Oslo University Hospital Rikshospitalet - Norwegian PSC Research Center, Department of Transplantation Medicine, Lithuanian University of Health Sciences - Department of Gastroenterology and Institute for Digestive Research, University of Medicine and Pharmacy - Institute for Gastroenterology and Hepatology, 3rd Medical Department, Saarland University - Department of Medicine II, Teaching Hospital No. 1 - of Gastroenterology and Hepatology with General Medicine Unit, Grigore T. Popa University of Medicine and Pharmacy - Department of Morpho-Functional Sciences I, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Erasmus MC University Medical Center - Department of Surgery, University of Regensburg - Institute of Pathology, University of Amsterdam - Department of Surgery, Hospital Universitario 12 de Octubre - Department of Medical Oncology, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, University of Regensburg - Institute of Pathology, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Sapienza University of Rome - Department of Movement, Human and Health Sciences, University of Copenhagen - Biotech Research and Innovation Centre, University of Salamanca - Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Sapienza University of Rome - Translational and Precision Medicine, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Instituto de Salud Carlos III” (ISCIII) - National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, The Christie NHS Foundation Trust - Department of Medical Oncology, Erasmus University Rotterdam (EUR) - Department of Surgery and University of the Basque Country - Department of Liver and Gastrointestinal Diseases
Downloads 70 (875,328)

Abstract:

Loading...

cholangiocarcinoma; International Classification of Diseases 11th edition (ICD-11); subtypes; diagnosis; risk factors; treatment; prognosis

3.

FOLFOX as Second-Line Chemotherapy for Advanced Biliary Tract Cancer

Number of pages: 50 Posted: 16 Oct 2020
The Christie NHS Foundation Trust - Department of Medical Oncology, Clatterbridge Cancer Centre, Imperial College London - Hammersmith Hospital, Department of Cancer Medicine, Guy's & St. Thomas’ NHS Foundation Trust - Guy’s Cancer, University Hospitals Birmingham NHS Foundation Trust, University of Nottingham, University Hospitals Bristol - Bristol Haematology and Oncology Centre, Government of the United Kingdom - Royal Free London NHS Foundation Trust, Weston Park Cancer Centre, Government of the United Kingdom - Oxford University Hospitals NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust, Hull University Teaching Hospitals NHS Trust, University of Southampton - University Hospital Southampton NHS Foundation Trust, Maidstone and Tunbridge Wells NHS Trust - Kent Oncology Centre, Government of the United Kingdom - Great Western Hospitals, University of Manchester - Manchester Clinical Trials Unit, University of Manchester - Manchester Clinical Trials Unit, Hampshire Hospitals NHS Foundation Trust, University of Manchester - Department of Health Economics, University College London - UCL Cancer Institute, The Christie NHS Foundation Trust - Department of Medical Oncology and Independent
Downloads 51 (1,052,702)
Citation 1

Abstract:

Loading...

biliary tract, advanced, second-line, chemotherapy, FOLFOX